INDIAN PHARMACOPOEIA COMMISSION
MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA
SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.
Tel No: 0120- 2783392, 2783400, 2783401; Fax: 2783311
E-mail: ipclab@vsnl.net, Web: www.ipc.gov.in

No. T.11013/02/2018-AR&D

Date: 05.11.2018

To,

1. Drugs Controller General (India)/ CDSCO Zonal Offices
2. All State Drug Controllers
3. Members of Scientific Body of the IPC
4. Members of Sub-Committees of Scientific Body of the IPC
5. Government Analysts
6. Directors of Drugs Testing Laboratories
7. IDMA/OPPI/BDMA/FSSAI/Small Scale Industry Associations

Subject: Deletion of the Usual Strength from the Monograph of 'Pioglitazone and Metformin Hydrochloride Tablets' from IP 2018-regarding

As you are aware that the Central Government vide Gazette Notification nos. S.O. 4379(E) to S.O. 4706(E) dated 07.09.2018 has prohibited 328 Fixed Dose Combinations (FDCs) for manufacture, sale or distribution with immediate effect as there is no therapeutic justification for ingredients contained in these 328 FDCs and these may invoke risk to human beings as mentioned in the notification.

In view of above notifications, Indian Pharmacopoeia Commission has deleted the usual strength "Pioglitazone, 15 mg and Metformin Hydrochloride, 850 mg" from the monograph of 'Pioglitazone and Metformin Hydrochloride Tablets' of Indian Pharmacopoeia (IP) 2018.

This is for notice and compliance.

(Dr. G. N. Singh)
Secretary-cum-Scientific Director